Advanced Lipid-Based Nanocarriers for Naratriptan Hydrochloride: A Path to Improved Migraine Treatment
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Migraine is a prevalent neurological disorder affecting a significant portion of the global population. It is characterized by frequent neurobiological or neurovascular disturbance, including heightened excitability of the central nervous system. Addressing these challenges, this study focuses on developing nanostructured lipids carriers (NLC) for intranasal drug delivery of naratriptan, aiming to provide a rapid and targeted treatment for migraine. The NLC was successfully formulated, characterized, and optimized using the Box Behnken Design (BBD). The optimized formulations underwent comprehensive characterization including assessments of % yield, encapsulation efficiency (%EE), particle size, Zeta potential, polydispersity index (PDI), surface morphology via scanning electron microscopy (SEM), crystallinity by X-ray Diffraction (XRD), and thermal behavior using differential scanning calorimetry (DSC), stability studies were conducted under varied conditions to evaluate formulation robustness. The optimized NLC formulation (NLCF2) demonstrated promising attributes with a % yield of 75.65±0.15 , % EE of 68.16±1.06 , particle size of 79.74±1.37, along with PDI of 0.315 , and Zeta Potential of -32.50. In-vivo pharmacodynamics studies using acetic acid-induced writhing and light/dark box models revealed significant efficacy of intranasal NLCs. Pharmacokinetic analysis, conducted using high-performance liquid chromatography (HPLC), demonstrated a 1.71-fold increase in drug concentration in the brain for the NLC formulation compared to the pure drug, underscoring enhanced bioavailability and brain targeting. The successful design and development of intranasal NLCs for migraine treatment represent a novel and effective approach to drug delivery. By facilitating rapid and targeted delivery, these nanocarriers have the potential to minimize systemic side effects and significantly improve the quality of life for individuals suffering from migraines.
